{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:19:56Z","timestamp":1790680796383,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T00:00:00Z","timestamp":1465516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T00:00:00Z","timestamp":1465516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/leu.2016.163","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T14:39:53Z","timestamp":1465569593000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Subtype-specific patterns of molecular mutations in acute myeloid leukemia"],"prefix":"10.1038","volume":"31","author":[{"given":"D","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Schnittger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Perglerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,10]]},"reference":[{"key":"BFleu2016163_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451\u2013458.","journal-title":"Br J Haematol"},{"key":"BFleu2016163_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620\u2013625.","journal-title":"Ann Intern Med"},{"key":"BFleu2016163_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJM198309153091103","volume":"309","author":"MM Le Beau","year":"1983","unstructured":"Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD . Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. N Engl J Med 1983; 309: 630\u2013636.","journal-title":"N Engl J Med"},{"key":"BFleu2016163_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/gcc.2870050109","volume":"5","author":"F Mitelman","year":"1992","unstructured":"Mitelman F, Heim S . Quantitative acute leukemia cytogenetics. Genes Chromosomes Cancer 1992; 5: 57\u201366.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2016163_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1046\/j.1365-2141.2002.03599.x","volume":"118","author":"T Haferlach","year":"2002","unstructured":"Haferlach T, Schoch C, Schnittger S, Kern W, Loffler H, Hiddemann W . Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. Br J Haematol 2002; 118: 426\u2013431.","journal-title":"Br J Haematol"},{"key":"BFleu2016163_CR6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","volume":"102","author":"C Schoch","year":"2003","unstructured":"Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T . AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003; 102: 2395\u20132402.","journal-title":"Blood"},{"key":"BFleu2016163_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/pro.2240","volume":"22","author":"L Federici","year":"2013","unstructured":"Federici L, Falini B . Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Protein Sci 2013; 22: 545\u2013556.","journal-title":"Protein Sci"},{"key":"BFleu2016163_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3324\/haematol.11669","volume":"93","author":"FP Kroschinsky","year":"2008","unstructured":"Kroschinsky FP, Schakel U, Fischer R, Mohr B, Oelschlaegel U, Repp R et al. Cup-like acute myeloid leukemia: new disease or artificial phenomenon? Haematologica 2008; 93: 283\u2013286.","journal-title":"Haematologica"},{"key":"BFleu2016163_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254\u2013266.","journal-title":"N Engl J Med"},{"key":"BFleu2016163_CR10","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","volume":"106","author":"S Schnittger","year":"2005","unstructured":"Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733\u20133739.","journal-title":"Blood"},{"key":"BFleu2016163_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3324\/haematol.11007","volume":"92","author":"B Falini","year":"2007","unstructured":"Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007; 92: 519\u2013532.","journal-title":"Haematologica"},{"key":"BFleu2016163_CR12","first-page":"42","volume":"3","author":"SC Raimondi","year":"1989","unstructured":"Raimondi SC, Dube ID, Valentine MB, Mirro Jr J, Watt HJ, Larson RA et al. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia. Leukemia 1989; 3: 42\u201347.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/sj.leu.2404068","volume":"20","author":"B Falini","year":"2006","unstructured":"Falini B, Bigerna B, Pucciarini A, Tiacci E, Mecucci C, Morris SW et al. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. Leukemia 2006; 20: 368\u2013371.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR14","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3109\/10428194.2013.856427","volume":"55","author":"A Kohlmann","year":"2013","unstructured":"Kohlmann A, Bacher U, Schnittger S, Haferlach T . Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. Leuk Lymphoma 2013; 55: 1725\u20131733.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2016163_CR15","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909\u20131918.","journal-title":"N Engl J Med"},{"key":"BFleu2016163_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez HF, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079\u20131089.","journal-title":"N Engl J Med"},{"key":"BFleu2016163_CR17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/leu.2013.273","volume":"28","author":"A Fasan","year":"2014","unstructured":"Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia 2014; 28: 794\u2013803.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR18","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2009-01-197871","volume":"114","author":"C Haferlach","year":"2009","unstructured":"Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009; 114: 3024\u20133032.","journal-title":"Blood"},{"key":"BFleu2016163_CR19","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/blood-2009-11-255976","volume":"117","author":"S Schnittger","year":"2011","unstructured":"Schnittger S, Dicker F, Kern W, Wendland N, Sundermann J, Alpermann T et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011; 117: 2348\u20132357.","journal-title":"Blood"},{"key":"BFleu2016163_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2012.262","volume":"27","author":"S Schnittger","year":"2013","unstructured":"Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013; 27: 82\u201391.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/leu.2011.97","volume":"25","author":"S Schnittger","year":"2011","unstructured":"Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T . Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011; 25: 1297\u20131304.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR22","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer (IARC): Lyon, 2008."},{"key":"BFleu2016163_CR23","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1182\/blood-2012-03-419622","volume":"120","author":"V Grossmann","year":"2012","unstructured":"Grossmann V, Schnittger S, Kohlmann A, Eder C, Roller A, Dicker F et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120: 2963\u20132972.","journal-title":"Blood"},{"key":"BFleu2016163_CR24","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","volume":"118","author":"Y Shen","year":"2011","unstructured":"Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118: 5593\u20135603.","journal-title":"Blood"},{"key":"BFleu2016163_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/leu.2008.19","volume":"22","author":"A Renneville","year":"2008","unstructured":"Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22: 915\u2013931.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR26","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/leu.2014.55","volume":"28","author":"R Kihara","year":"2014","unstructured":"Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients 2. Leukemia 2014; 28: 1586\u20131595.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR27","first-page":"110","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"DA Arber","year":"2008","unstructured":"Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman J, Porwit A et alAcute myeloid leukemia with recurrent genetic abnormalities In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al(eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC): Lyon, 2008; pp 110\u2013123."},{"key":"BFleu2016163_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.leu.2402329","volume":"16","author":"C Schoch","year":"2002","unstructured":"Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53\u201359.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/gcc.20433","volume":"46","author":"C Haferlach","year":"2007","unstructured":"Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 2007; 46: 494\u2013499.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2016163_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/gcc.10088","volume":"35","author":"C Schoch","year":"2002","unstructured":"Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002; 35: 20\u201329.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2016163_CR31","volume-title":"ISCN 2013: An International System for Human Cytogenetic Nomenclature","author":"LG Shaffer","year":"2013","unstructured":"Shaffer LG, McGowan-Jordan J, Schmid M . ISCN 2013: An International System for Human Cytogenetic Nomenclature. Karger: Basel, New York, 2013."},{"key":"BFleu2016163_CR32","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1182\/blood-2004-03-1036","volume":"104","author":"W Kern","year":"2004","unstructured":"Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078\u20133085.","journal-title":"Blood"},{"key":"BFleu2016163_CR33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.beha.2010.06.007","volume":"23","author":"W Kern","year":"2010","unstructured":"Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T . The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010; 23: 379\u2013390.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu2016163_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","volume":"100","author":"S Schnittger","year":"2002","unstructured":"Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59\u201366.","journal-title":"Blood"},{"key":"BFleu2016163_CR35","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","volume":"111","author":"U Bacher","year":"2008","unstructured":"Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S . Prognostic relevance of FLT3-TKD mutations in AML: the combination matters\u2014-an analysis of 3082 patients. Blood 2008; 111: 2527\u20132537.","journal-title":"Blood"},{"key":"BFleu2016163_CR36","first-page":"881","volume":"90","author":"M Weisser","year":"2005","unstructured":"Weisser M, Kern W, Schoch C, Hiddemann W, Haferlach T, Schnittger S . Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. Haematologica 2005; 90: 881\u2013889.","journal-title":"Haematologica"},{"key":"BFleu2016163_CR37","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/leu.2013.65","volume":"27","author":"A Roller","year":"2013","unstructured":"Roller A, Grossmann V, Bacher U, Poetzinger F, Weissmann S, Nadarajah N et al. Landmark analysis of DNMT3A mutations in hematological malignancies. Leukemia 2013; 27: 1573\u20131578.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR38","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1182\/blood-2010-02-267955","volume":"116","author":"S Schnittger","year":"2010","unstructured":"Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T . IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010; 116: 5486\u20135496.","journal-title":"Blood"},{"key":"BFleu2016163_CR39","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","volume":"28","author":"A Kohlmann","year":"2010","unstructured":"Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, Kazak B et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010; 28: 3858\u20133865.","journal-title":"J Clin Oncol"},{"key":"BFleu2016163_CR40","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1182\/blood-2005-08-3522","volume":"107","author":"U Bacher","year":"2006","unstructured":"Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S . Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847\u20133853.","journal-title":"Blood"},{"key":"BFleu2016163_CR41","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2011.326","volume":"26","author":"S Weissmann","year":"2012","unstructured":"Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012; 26: 934\u2013942.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR42","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/leu.2014.243","volume":"29","author":"MT Krauth","year":"2014","unstructured":"Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M et al. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia 2014; 29: 660\u2013667.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/leu.2010.22","volume":"24","author":"C Haferlach","year":"2010","unstructured":"Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010; 24: 1065\u20131069.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR44","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1038\/leu.2013.144","volume":"27","author":"V Grossmann","year":"2013","unstructured":"Grossmann V, Bacher U, Haferlach C, Schnittger S, Potzinger F, Weissmann S et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. Leukemia 2013; 27: 1940\u20131943.","journal-title":"Leukemia"},{"key":"BFleu2016163_CR45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s11912-002-0032-0","volume":"4","author":"C Schoch","year":"2002","unstructured":"Schoch C, Haferlach T . Cytogenetics in acute myeloid leukemia. Curr Oncol Rep 2002; 4: 390\u2013397.","journal-title":"Curr Oncol Rep"},{"key":"BFleu2016163_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neo.2014.06.002","volume":"16","author":"HW Kao","year":"2014","unstructured":"Kao HW, Liang DC, Wu JH, Kuo MC, Wang PN, Yang CP et al. Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia 4. Neoplasia 2014; 16: 481\u2013488.","journal-title":"Neoplasia"},{"key":"BFleu2016163_CR47","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059\u20132074.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016163","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:20:44Z","timestamp":1648743644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,10]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFleu2016163"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.163","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,10]]},"assertion":[{"value":"22 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TH, WK and CH have equity ownership of the MLL Munich Leukemia Laboratory GmbH. DR and KP are employed by the MLL Munich Leukemia Laboratory GmbH and the MLL2 s.r.o., respectively.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}